SenzaGen received another follow-up order from the same global chemicals leader that ordered tests earlier this year. Once again, the order includes testing with SenzaGen?s innovative non-animal skin sensitization test method, GARD®skin. The order is worth approximately SEK 0.8 million and the testing will be performed at the Company's GLP-certified lab in Lund during the first half of 2024.

This is the second order from this customer in a short period of time, following successful evaluation of GARD®skin in 2022?2023. The testing is linked to one of the company?s research and development projects aiming to assess whether new product candidates could potentially cause skin allergies. The GARD® test platform determines whether chemicals can cause allergies and targets companies looking to increase the accuracy of their test results and ensure product safety while avoiding animal studies.

The unique platform combines genomic data from human cells with machine learning, making the method both more effective and more accurate than both traditional animal-based methods and other non-animal methods for this type of challenging chemicals.